EA201501054A1 - Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы - Google Patents
Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозыInfo
- Publication number
- EA201501054A1 EA201501054A1 EA201501054A EA201501054A EA201501054A1 EA 201501054 A1 EA201501054 A1 EA 201501054A1 EA 201501054 A EA201501054 A EA 201501054A EA 201501054 A EA201501054 A EA 201501054A EA 201501054 A1 EA201501054 A1 EA 201501054A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tragose
- myopathies
- parental
- proteins
- introduction
- Prior art date
Links
- 208000021642 Muscular disease Diseases 0.000 title 1
- 201000009623 Myopathy Diseases 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000004849 abnormal protein aggregation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/04—Disaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361820278P | 2013-05-07 | 2013-05-07 | |
| PCT/IL2014/050411 WO2014181333A2 (en) | 2013-05-07 | 2014-05-07 | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201501054A1 true EA201501054A1 (ru) | 2016-04-29 |
Family
ID=51022384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201501054A EA201501054A1 (ru) | 2013-05-07 | 2014-05-07 | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10493023B2 (enExample) |
| EP (2) | EP2994145B1 (enExample) |
| JP (5) | JP6837835B2 (enExample) |
| KR (1) | KR20160009617A (enExample) |
| AU (5) | AU2014264228A1 (enExample) |
| CA (2) | CA3239805A1 (enExample) |
| CR (1) | CR20150637A (enExample) |
| EA (1) | EA201501054A1 (enExample) |
| IL (1) | IL241757B (enExample) |
| MD (1) | MD20150120A2 (enExample) |
| MX (1) | MX2015015355A (enExample) |
| PE (1) | PE20160012A1 (enExample) |
| SG (1) | SG11201509030TA (enExample) |
| WO (1) | WO2014181333A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9084720B2 (en) * | 2013-05-07 | 2015-07-21 | BioBlast Pharma Ltd. | Compositions and methods for treating oculopharyngeal muscular dystrophy |
| US20220288096A1 (en) * | 2013-05-07 | 2022-09-15 | Seelos Therapeutics, Inc. | Compositions and methods for treating an aggregation disease or disorder |
| SG11201509030TA (en) | 2013-05-07 | 2015-11-27 | Bio Blast Pharma Ltd | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose |
| WO2017136922A1 (en) * | 2016-02-08 | 2017-08-17 | Junaxo, Inc. | Use of trehalose for treatment of neurological diseases |
| JP7302871B2 (ja) | 2016-04-21 | 2023-07-04 | ベイラー カレッジ オブ メディスン | リソソーム蓄積障害およびリソソーム機能不全によって特徴付けられる障害を治療するための組成物および方法 |
| BR112020003119A2 (pt) | 2017-08-14 | 2020-10-13 | Prilenia Neurotherapeutics Ltd. | método de tratamento de esclerose lateral amiotrófica com pridopidina |
| US11844808B2 (en) | 2018-01-16 | 2023-12-19 | Women & Infants Hospital Of Rhode Island | Methods and compositions for treating pre-eclampsia |
| IL291799A (en) * | 2019-10-01 | 2022-06-01 | Seelos Therapeutics Inc | Trehalose formulations and uses thereof |
| MX2022010006A (es) * | 2020-02-13 | 2022-09-19 | Prilenia Neurotherapeutics Ltd | Terapia combinada para el tratamiento de la amiotrofica lateral con pridopidina y otro agente activo. |
| WO2022013940A1 (ja) | 2020-07-14 | 2022-01-20 | オリンパス株式会社 | 嚥下検査用システム、嚥下検査方法及び嚥下検査プログラムを記録した記録媒体 |
| CN116966192A (zh) * | 2022-09-26 | 2023-10-31 | 西安文理学院 | 海藻糖在制备sca3疾病治疗药物中的应用 |
| AU2023403437A1 (en) * | 2022-11-30 | 2025-06-19 | GLD Debt Acquisition 2025-1, Inc. | Trehalose for treating huntington's disease |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3782404A (en) | 1972-06-14 | 1974-01-01 | Commercial Shearing | Adjustable, metered, directional flow control arrangements |
| JPS4950521U (enExample) | 1972-08-14 | 1974-05-02 | ||
| JPS516109B2 (enExample) | 1972-12-28 | 1976-02-25 | ||
| JPS557829Y2 (enExample) | 1974-07-01 | 1980-02-21 | ||
| JPS516109A (en) | 1974-07-05 | 1976-01-19 | Toshiba Tungaloy Co Ltd | Aruminaatankachitan chitsukachitankeishoketsugokin |
| JP4033510B2 (ja) | 1995-12-27 | 2008-01-16 | ロート製薬株式会社 | トレハロースを含有する眼科用医薬組成物 |
| WO1997024129A1 (en) | 1995-12-27 | 1997-07-10 | Rohto Pharmaceutical Co., Ltd. | Pharmaceutical composition containing trehalose |
| JP3455633B2 (ja) | 1996-06-28 | 2003-10-14 | 味の素ファルマ株式会社 | 潰瘍性大腸炎の予防又は治療剤 |
| US6440446B1 (en) | 1998-04-22 | 2002-08-27 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Agent for anti-osteoporosis |
| US6602865B1 (en) | 1998-11-16 | 2003-08-05 | Ivax Drug Research Institute, Ltd. | Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds |
| JP2001302517A (ja) * | 2000-04-24 | 2001-10-31 | Tokyo Univ Of Pharmacy & Life Science | 脳浮腫の予防治療薬 |
| AU781975B2 (en) | 2000-09-14 | 2005-06-23 | Hayashibara Co., Ltd | Pharmaceutical composition for ophthalmic use |
| JP4754066B2 (ja) | 2000-12-22 | 2011-08-24 | 株式会社林原生物化学研究所 | 抗関節障害剤 |
| JP4255101B2 (ja) * | 2002-03-15 | 2009-04-15 | 独立行政法人理化学研究所 | 神経変性疾患の治療薬 |
| WO2004060343A1 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics | Antibody-containing particles and compositions |
| KR101217382B1 (ko) | 2003-02-13 | 2012-12-31 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | α,α-트레할로오스의 당질 유도체를 함유하는 것을 특징으로 하는 피부 외용제 |
| US20050215562A1 (en) * | 2003-06-23 | 2005-09-29 | Patrick Tremblay | Methods for treating protein aggregation disorders |
| US20050100637A1 (en) * | 2003-11-12 | 2005-05-12 | Robert Murray | Carbohydrate and electrolyte replacement composition |
| US20060099567A1 (en) * | 2004-04-08 | 2006-05-11 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
| US20060257391A1 (en) * | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
| CA2608198A1 (en) | 2005-05-13 | 2006-11-23 | Whitehead Institute For Biomedical Research | Modulators of alpha-synuclein toxicity |
| MY142987A (en) | 2005-06-08 | 2011-02-14 | Hayashibara Biochem Lab | Solution for tissue adhesion prevention and method for tissue adhesion prevention |
| JP2006342108A (ja) * | 2005-06-09 | 2006-12-21 | Mitsubishi Chemicals Corp | アミロスフェロイドにより発生する疾患の予防治療剤 |
| WO2007018124A1 (ja) | 2005-08-11 | 2007-02-15 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | コラーゲン産生増強剤とその用途 |
| JP5192804B2 (ja) | 2005-11-30 | 2013-05-08 | 日清オイリオグループ株式会社 | トレハロース脂肪酸エステル組成物 |
| JP4950521B2 (ja) | 2006-03-08 | 2012-06-13 | 公益財団法人野口研究所 | トレハロース誘導体とその製造法 |
| WO2007111214A1 (ja) | 2006-03-27 | 2007-10-04 | Otsuka Chemical Co., Ltd. | トレハロース化合物および該化合物を含有する医薬 |
| CN100571707C (zh) | 2006-07-24 | 2009-12-23 | 凌沛学 | 含有海藻糖的关节腔内注射给药制剂 |
| EP2123662B1 (en) | 2007-01-31 | 2013-12-04 | Glytech, Inc. | Trehalose compound, process for production of the compound, and immuno-stimulative agent comprising the compound |
| EP2198869B1 (en) * | 2007-02-23 | 2015-09-16 | Next 21 K.K. | Trehalose for the treatment or prevention of vasospasm |
| WO2008133884A2 (en) | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| US8206751B2 (en) * | 2007-10-31 | 2012-06-26 | Diffusion Pharmaceuticals Llc | Class of therapeutics that enhance small molecule diffusion |
| JP2009249292A (ja) * | 2008-04-01 | 2009-10-29 | Toray Ind Inc | ポリリン酸を安定化剤とするエリスロポエチン溶液製剤 |
| WO2010008860A1 (en) * | 2008-06-23 | 2010-01-21 | President And Fellows Of Harvard College | Modulation of neurodegenerative disease by modulating xbp-1 activity |
| KR101021078B1 (ko) * | 2008-07-22 | 2011-03-14 | 포항공과대학교 산학협력단 | 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물 |
| WO2010050178A1 (ja) | 2008-10-31 | 2010-05-06 | 大塚化学株式会社 | トレハロース化合物、その製造方法、及び該化合物を含有する医薬 |
| BRPI0921845A2 (pt) * | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
| PT3112358T (pt) | 2008-12-10 | 2020-06-23 | Wista Lab Ltd | Sais de xantílio 3,6-dissubstituídos |
| EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| US20120121580A1 (en) * | 2009-07-28 | 2012-05-17 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| JP5869882B2 (ja) | 2010-03-05 | 2016-02-24 | 株式会社林原 | インスリン抵抗性の予防及び／又は改善剤 |
| PL3626258T3 (pl) | 2010-06-25 | 2022-01-17 | Shire Human Genetic Therapies, Inc. | Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun |
| CN101914118B (zh) | 2010-08-06 | 2012-07-04 | 山东大学 | 海藻糖衍生物及其制备方法与应用 |
| US20140066439A1 (en) * | 2010-11-10 | 2014-03-06 | Katholieke Universiteit Leuen, K.U.Leuven R&D | Osteoclast activity |
| US9186356B2 (en) | 2011-01-08 | 2015-11-17 | Academia Sinica | Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) |
| JP6175431B2 (ja) | 2011-06-20 | 2017-08-02 | アイカーン スクール オブ メディシン アット マウント サイナイ | ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法 |
| US8623839B2 (en) * | 2011-06-30 | 2014-01-07 | Depuy Mitek, Llc | Compositions and methods for stabilized polysaccharide formulations |
| US20130310467A1 (en) | 2012-03-06 | 2013-11-21 | The Nisshin Oillio Group, Ltd. | Trehalose fatty acid ester composition |
| JP5432322B2 (ja) | 2012-05-08 | 2014-03-05 | 株式会社大塚製薬工場 | トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液 |
| US20130312784A1 (en) | 2012-05-24 | 2013-11-28 | For Your Ease Only, Inc. | Cosmetic organizer |
| US20140032304A1 (en) | 2012-07-27 | 2014-01-30 | Google Inc. | Determining a correlation between presentation of a content item and a transaction by a user at a point of sale terminal |
| JP2014139160A (ja) | 2012-12-21 | 2014-07-31 | Masaaki Hayashibara | 脳機能改善剤及び脳機能改善用食品 |
| US20220288096A1 (en) | 2013-05-07 | 2022-09-15 | Seelos Therapeutics, Inc. | Compositions and methods for treating an aggregation disease or disorder |
| SG11201509030TA (en) | 2013-05-07 | 2015-11-27 | Bio Blast Pharma Ltd | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose |
| US9084720B2 (en) | 2013-05-07 | 2015-07-21 | BioBlast Pharma Ltd. | Compositions and methods for treating oculopharyngeal muscular dystrophy |
| JP6130224B2 (ja) | 2013-05-27 | 2017-05-17 | 公益財団法人微生物化学研究会 | 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物 |
| TWI507197B (zh) | 2013-07-17 | 2015-11-11 | Univ Nat Taiwan Normal | 醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途 |
| US10906981B2 (en) | 2013-07-19 | 2021-02-02 | The Regents Of The University Of California | Compositions and methods related to structures that cross the blood brain barrier |
| EP3220906B1 (en) | 2014-11-19 | 2022-03-02 | Rush University Medical Center | Compositions and methods for treating lysosomal disorders |
| US20160303150A1 (en) | 2015-04-16 | 2016-10-20 | BioBlast Pharma Ltd. | Deuterated trehalose formulations and uses thereof |
| WO2017136533A1 (en) | 2016-02-03 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Methods for treating diagnosing, and monitoring treatment of mucopolysaccharidoses |
| JP7302871B2 (ja) | 2016-04-21 | 2023-07-04 | ベイラー カレッジ オブ メディスン | リソソーム蓄積障害およびリソソーム機能不全によって特徴付けられる障害を治療するための組成物および方法 |
| IL291799A (en) | 2019-10-01 | 2022-06-01 | Seelos Therapeutics Inc | Trehalose formulations and uses thereof |
-
2014
- 2014-05-07 SG SG11201509030TA patent/SG11201509030TA/en unknown
- 2014-05-07 PE PE2015002367A patent/PE20160012A1/es not_active Application Discontinuation
- 2014-05-07 KR KR1020157034700A patent/KR20160009617A/ko not_active Withdrawn
- 2014-05-07 AU AU2014264228A patent/AU2014264228A1/en not_active Abandoned
- 2014-05-07 EP EP14733380.1A patent/EP2994145B1/en active Active
- 2014-05-07 JP JP2016512480A patent/JP6837835B2/ja active Active
- 2014-05-07 CA CA3239805A patent/CA3239805A1/en active Pending
- 2014-05-07 MD MDA20150120A patent/MD20150120A2/ro not_active Application Discontinuation
- 2014-05-07 EP EP22216238.0A patent/EP4218769A3/en active Pending
- 2014-05-07 CA CA2911399A patent/CA2911399C/en active Active
- 2014-05-07 EA EA201501054A patent/EA201501054A1/ru unknown
- 2014-05-07 WO PCT/IL2014/050411 patent/WO2014181333A2/en not_active Ceased
- 2014-05-07 MX MX2015015355A patent/MX2015015355A/es unknown
- 2014-05-07 US US14/889,727 patent/US10493023B2/en active Active
-
2015
- 2015-09-21 IL IL241757A patent/IL241757B/en active IP Right Grant
- 2015-12-04 CR CR20150637A patent/CR20150637A/es unknown
-
2019
- 2019-04-11 JP JP2019075517A patent/JP2019142907A/ja active Pending
- 2019-06-26 AU AU2019204513A patent/AU2019204513B2/en active Active
- 2019-07-02 US US16/460,046 patent/US10869831B2/en active Active
-
2020
- 2020-11-26 AU AU2020277197A patent/AU2020277197A1/en not_active Abandoned
-
2021
- 2021-06-08 JP JP2021095562A patent/JP2021152032A/ja active Pending
- 2021-06-23 US US17/355,607 patent/US20220117883A1/en not_active Abandoned
-
2023
- 2023-01-11 JP JP2023002536A patent/JP2023040211A/ja active Pending
- 2023-01-20 AU AU2023200303A patent/AU2023200303A1/en not_active Abandoned
- 2023-04-05 US US18/131,161 patent/US12239733B2/en active Active
-
2025
- 2025-03-07 JP JP2025036306A patent/JP2025087858A/ja active Pending
- 2025-03-13 AU AU2025201824A patent/AU2025201824A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
| BR112017005736A2 (pt) | macrociclos peptidomiméticos e formulações dos mesmos | |
| CY1125326T1 (el) | Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων. | |
| MX2022013517A (es) | Composiciones de aminoacidos y metodos de tratamiento de enfermedades hepaticas. | |
| EA201591751A1 (ru) | Трипептидные эпоксикетонные ингибиторы протеазы | |
| EA201690212A8 (ru) | Способы лечения или профилактики офтальмологических патологических состояний | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| EA201991484A1 (ru) | Лекарственные формы энзалутамида | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| EA201590343A1 (ru) | Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| MX375752B (es) | Inhibidores de tirosina quinasa de bruton. | |
| EA202090683A3 (ru) | Способы и композиции для лечения рака | |
| EA201591535A1 (ru) | Замещенные производные 3-фенилпропиламина для лечения офтальмологических заболеваний и расстройств | |
| EA201992772A1 (ru) | Инъецируемые препараты длительного действия, содержащие изоксазолиновое действующее вещество, способы и применение | |
| EA201591752A1 (ru) | Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
| CY1119957T1 (el) | Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος | |
| EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений |